Table 3.

Rationale for GLP-1 Usage

Drug	Involvement in Obesity	The Rationale for GLP-1 Usage
Exenatide	Enhancing Weight Loss Maintenance	Improve glucose tolerance. Induction of weight loss by lowering appetite and the rate at which food moves through the digestive system. For severely obese children and obesity caused by the Prader-Willi Syndrome (PWS).
Metformin-Glp-1 combination	Evaluate the effect of metformin-GLP-1 Receptor agonist combination versus metformin-Diane-35 combination treatment on lipid metabolism and cardiovascular risks	GLP-1 receptor agonists lower blood sugar and control weight by reducing food intake and inhibiting gastric emptying. PCOS patients who are overweight might benefit from this treatment.
Semaglutide	Examine semaglutide’s effect on metabolic syndrome reduction, especially improving insulin sensitivity and lowering hepatic fat	The combination of testosterone and obesity in obese patients with polycystic ovarian syndrome can increase metabolic diseases such as fatty liver disease and insulin resistance.
Liraglutide	Evaluate the effect of liraglutide on additional weight loss after bariatric surgery	Severe obesity is treated with metabolic bariatric surgery. The majority of adolescents who undergo this surgery still have obesity 1 year later. Liraglutide combined with surgery was studied to assess its effect.